Objectives/Hypothesis: Primary curative treatment of advanced laryngeal cancer may include surgery or chemoradiation, although recommendations vary and both are associated with complications. We evaluated predictors and trends in the use of these modalities and compared rates of complications and overall survival in a population-based cohort of older adults.
INTRODUCTION
Cancer of the larynx is among the most common cancers of the upper aerodigestive tract, with almost 13,000 new cases diagnosed in the United States in 2010. 1 Definitive treatment for advanced stage laryngeal cancer (stage III or IV) consists of either total laryngectomy (TL) or chemoradiation (CTRT).
2 Radiotherapy (RT) alone has been shown to have poorer efficacy than CTRT and is reserved for the small group of patients for whom substantial comorbidity threatens the safe administration of surgery or CTRT. 3, 4 An evolution in the treatment of advanced laryngeal cancer (stage III and IV) has occurred over the past 2 decades, with a fall in the use of primary surgery and a corresponding rise in the use of nonoperative treatment. [5] [6] [7] [8] [9] [10] This trend originated with the publication of a landmark Veteran Affairs study in 1991, which showed that induction chemotherapy followed by definitive radiation could preserve the larynx without compromising overall survival. 11 In 2003, the Radiation Therapy Oncology Group 91-11 trial concluded that concurrent CTRT improved local control compared with induction chemotherapy followed by RT and should be considered the standard of care for patients with T3 disease who desire laryngeal preservation. 4 Although the adoption of primary CTRT as the standard of care has clearly benefited many patients, its increased use has coincided with a rise in functional complications and decreased overall survival in older patients and those with T4 disease, respectively. 5, 7, 9, [12] [13] [14] Furthermore, salvage surgery as a final curative treatment strategy for patients treated with organpreserving CTRT can be technically complex and have a significant impact on patient morbidity. 15, 16 At the population level, little is known about treatment patterns, the proportion of patients receiving various treatment modalities, and the factors that influence the type of treatment received. The treatment of older patients is Additional Supporting Information may be found in the online version of this article.
From of particular concern, with evidence indicating a decreasing benefit of chemotherapy with increasing patient age, and a lack of significant benefit when chemotherapy is added to RT in patients over the age of 70. 17, 18 The objectives of this study were to evaluate predictors and trends in the use of CTRT and TL and to compare rates of treatment-related complications and overall survival between these modalities in a population-based cohort of older adults.
MATERIALS AND METHODS

Data
We used Surveillance Epidemiology and End Results (SEER) cancer registry data linked with Medicare claims. SEER is a National Cancer Institute (NCI)-sponsored consortium of population-based cancer registries covering approximately 28% of Americans in selected states and geographic areas. 19 The SEER registries collect information regarding site and extent of disease, clinical and pathologic stage, first course of cancer-directed therapy, and sociodemographic characteristics for all newly diagnosed cancer cases-with active follow-up for date and cause of death. Medicare is the primary health insurer for 97% of the U.S. population aged 65 years and older and covers inpatient hospital care (part A) and outpatient care and physician services (part B). The SEER-Medicare files were used in accordance with a data-use agreement between the NCI and the Centers for Medicare and Medicaid Services (CMS). This study was approved by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center.
Study Cohort
We identified Medicare beneficiaries aged 66 years or older with a pathologically confirmed primary diagnosis of advanced squamous cell laryngeal cancer (stage III or IV) between January 1, 1999, and December 31, 2007. 20 Patients were categorized into one of two mutually exclusive primary treatment categories, TL or CTRT, based on Medicare claims within 6 months following diagnosis. Primary TL consisted of TL alone (N 5 103), TL with postoperative RT (N 5 184), or CTRT (N 5 41)-and included TL with or without a neck dissection. Primary concurrent CTRT included any claim for RT, at least two claims for chemotherapy, and no claim for TL within the initial 6-month treatment period. In order to minimize possible misclassification of induction CTRT as concurrent therapy, we excluded patients whose first claim for RT was more than 60 days after their first claim for CT (N 5 38) (see Appendix Table II) . From both treatment groups, we excluded patients enrolled in a Medicare-managed care plan and those who did not have continuous Medicare coverage from 1 year prior to diagnosis through death or end of follow-up. Patients diagnosed only at the time of death, who had a history of another malignancy, or who had distant metastases at diagnosis were also excluded.
Outcomes
We evaluated predictors and trends in the use of TL versus CTRT, differences between these modalities in treatment-related complications, and overall survival-as well as the rate of salvage surgery in those receiving CTRT. Complications included mucositis, xerostomia, dysphagia, esophageal dilation, esophagitis, pneumonia, sepsis, and venous or pulmonary thromboembolism. These complications were identified by relevant diagnosis and procedure codes between the date of first treatment and death or end of follow-up (see Appendix Table III ). The number of patients who had an inpatient admission or emergency room (ER) visit for any of the above diagnoses was also identified. Tracheostomy and feeding tube placements were evaluated overall, as well as prior to and following treatment initiation. Long-term feeding tube used was based on claims in the Durable Medical Equipment file for nutritional support or a claim for subsequent feeding tube insertion more than 1 year after initial tube insertion. The rate of salvage surgery in the CTRT group was defined as a claim for TL more than 6 months after diagnosis.
Covariates
Demographic characteristics included patient age, race, geographic location, marital status, and residence in a metropolitan versus nonmetropolitan county. Median income in the census tract of residence was used as a marker of socioeconomic status and classified in quartiles. Disease characteristics included clinical tumor stage, site of disease in the larynx, lymph node involvement, and year of diagnosis. Comorbidity was estimated using a modification of the Charlson Comorbidity index based on inpatient, outpatient, and physician claims in the year prior to laryngeal cancer diagnosis.
21,22
Statistical Analysis Differences between groups in treatment complications were assessed with chi-square or Fisher's exact tests, as appropriate based on cell counts. We estimated the association between primary treatment modality and the risk of death from any cause using propensity score methods to minimize bias related to the nonrandom assignment of treatment. 23, 24 The propensity to receive surgery was modeled as a function of age, sex, race, census tract median income, marital status, urban-rural residence, geographic region, tumor site, T classification, lymph node involvement, comorbidity score and year of diagnosis using multivariable logistic regression. Death from any cause was estimated in two proportional hazards regression models: one with the propensity score included as a continuous covariate and the other stratified by propensity score quintiles. 25 In sensitivity analyses, we examined the impact of excluding patients with T4 disease. 26 All analyses were performed in SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Cohort Characteristics and Treatment
We identified 759 patients with advanced laryngeal cancer of whom 57% received CTRT and 43% had primary surgery (Table I) disease and 34% of patients with T3 disease received TL, respectively. Of those who had T4 disease, 95% were classified as T4a laryngeal cancer. The proportion of patients receiving surgery decreased significantly over the study period (P < 0.0001). This finding persisted, even when we excluded cases diagnosed prior to 2000 after several new registries were added to the SEER program ( Fig. 1) . Adjusted for other characteristics, patients with T4 disease had a greater odds of receiving TL, whereas those with supraglottic cancers had lower odds of TL (Table II) .
Complications and Salvage Surgery
Although a significantly greater proportion of CTRT patients had claims for mucositis, xerostomia, and dysphagia (P < 0.0001), the proportion of patients requiring a hospital or ER admission for a treatment-related complication was comparable between the treatment groups (Table III) .
Fifty-seven percent of CTRT patients had a feeding tube inserted following treatment initiation compared with 33% of TL patients (P < 0.0001) (Table III) . Fourteen percent and 7% of CTRT and TL patients were still tube-dependent at 1 year, respectively. Twenty-two percent of CTRT patients and 19% of TL patients had a tracheostomy prior to treatment initiation, and 19% of CTRT patients had a tracheostomy following treatment initiation. All TL patients have a tracheal stoma upon completion of the surgical procedure.
Eleven percent of CTRT patients (N 5 47) had a claim for TL following the 6-month initial treatment period, and the median time to salvage TL was 1 year. Other site includes subglottis, overlapping tumors and cancer of the larynx NOS. Of those who had T4 disease, 95% had T4a and 5% had T4b disease, respectively.
Cell counts < 11 not shown in accordance with the SEER-Medicare Data Use Agreement.
CTRT 5chemoradiation; NOS 5 not otherwise specified; NS 5 not statistically significant at P < 0.05; TL 5 total laryngectomy.
Survival
Unadjusted for any potential confounders, neither treatment modality was associated with a survival advantage. Controlling for the likelihood of receiving treatment, TL was associated with a 18% lower risk of death from any cause compared with CTRT, stratified by propensity score quintile (adjusted hazard ratio 0.82; P < 0.05) (Table IV) . Results were similar when propensity score was included as a continuous covariate. Within propensity score quintiles, most characteristics were wellbalanced between patients who received TL and those who received CTRT (data not shown). The survival advantage associated with TL was greatest among patients in the highest propensity score quintile, and this group differed from the other quintiles in several ways. Notably, the share of patients with a T4 tumor in quintile 5 was almost three times greater than in the rest of the cohort (Fig. 2) . In sensitivity analyses, excluding patients with T4 disease, neither treatment modality was associated with a survival advantage.
DISCUSSION
Following the publication of reports supporting CTRT in advanced laryngeal cancer, specifically in T3 disease, the use of TL has declined significantly over time. 4, 5, 9, 11, 27, 28 The decreased use of surgery that we observed during the study period is not surprising. This trend presumably reflects enthusiasm for organpreserving treatment approaches and clinical trial results suggesting oncologic outcomes comparable to those achieved with surgery. 11, 27, 29, 30 Although this approach has been greatly effective in many patients, lower rates of organ preservation and higher complication rates in patients with T4 disease have prompted the recommendation of primary TL in this group.
2,31-33 Our examination of a large, populationbased cohort showed that 34% of patients with T3 disease received TL. Of significance was the finding that a nonnegligible fraction of T4 patients received organ preservation therapy (27%), despite NCCN guidelines advising TL. 2, 33 These findings suggest Other site includes subglottis, overlapping tumors, and cancer of the larynx not otherwise specified.
CI 5 confidence interval; CTRT 5chemoradiation; OR 5 odds ratio; TL 5 total laryngectomy. wide variations in practice and the influence of other nonclinical factors such as physician specialty and geographic location in treatment choice 10, [33] [34] [35] In fact, a Canadian population-based study reported variations in TL rates of 6% to 53% among patients with stage III and IV disease-and large cause-specific survival differences among cases of potentially comparable prognoses. 35 Inferences about the association between treatment and survival in an observational setting must be made cautiously. Our analysis of survival within propensity score quintiles suggests that the greatest apparent survival advantage is derived by patients with the greatest predicted probability of receiving surgery. This subgroup included a disproportionate share of patients with T4 disease, glottic tumors, black Adjusted HR for impact of TL (compared with CTRT) on risk of death, adjusted for propensity to receive TL. Propensity score estimated as function of age, sex, race, census tract median income, marital status, urban-rural residence, geographic region, tumor site, clinical T stage, lymph node involvement, comorbidity score, and year of diagnosis.
CI 5 confidence interval; CTRT 5chemoradiation; HR 5 hazard ratio; TL 5 total laryngectomy.
patients, and those of lower socioeconomic classes. Indeed when patients with T4 cancers were excluded from the analysis, neither treatment modality was associated with a survival benefit. 5, 7 Although it is impossible to infer the cause of death from this analysis, these survival outcomes may be explained by the fact that CTRT is much less efficacious when the cartilaginous skeleton of the larynx is invaded by cancer. In addition, invasion of the laryngeal cartilaginous framework can result in an irretrievably dysfunctional larynx once treated with CTRT, thereby causing severe late toxicity, particularly in the older population. 26, 27 Perhaps more important, our findings suggest that patients who receive surgery have been well-selected for TL; therefore, they represent those most likely to benefit from it.
Acute, often severe treatment-related toxicities leading to the interruption or modification of RT delivery may compromise the value of CTRT, particularly among older patients and those with coexisting medical conditions or decreased performance status. 26, [36] [37] [38] [39] Although our study demonstrated that a greater proportion of CTRT patients experienced RT-related toxicities including mucositis, xerostomia, and dysphagia, the proportion of patients experiencing esophageal stricture requiring dilation, esophagitis, sepsis, pneumonia, or thrombosis did not differ significantly between the groups. More important, the rate of hospital admissions or ER visits between those receiving CTRT and TL was comparable.
Although prolonged disease-free survival and improved cure rates are two of the most important objectives of cancer therapy; the implicit purpose of organ preservation is improved laryngeal function and quality of life. 40 Unfortunately, organ preservation does not necessarily result in the preservation of function and does not correlate with the absence of chronic dysphagia, dependence on feeding tubes, or a tracheostomy. 14, 41, 42 Although the anticipated sequela of total laryngectomy, including a tracheostomy and loss of laryngeal speech, cause considerable physical and psychosocial morbidity to the patient, our results suggest that a number of patients initially treated with organ-preserving therapy will have both poor functional outcomes related to the inability to eat and the inability to breathe through their larynx. 43, 44 Fifty-seven percent of older patients who were initially treated with CTRT required a feeding tube following treatment, and 14% still required nutritional support at 1 year. Comparable proportions of TL (19%) and CTRT (22%) patients required airway intervention prior to treatment initiation, an indication that these TL patients were appropriately treated but that perhaps those receiving CTRT should have been more strongly guided toward surgery.
The rate of treatment failure was relatively low compared to what has been reported previously. 41, 45, 46 Only 11% of CTRT patients required salvage surgery following the initial 6-month treatment period. It is possible that a portion of patients who received a tracheostomy following CTRT initiation (19%) may have done so as a result of tumor persistence or recurrence rather than as a result of a complication of therapy.
Several limitations of our analysis should be noted. Whereas we were able to control for important patient and tumor characteristics, there may have been residual confounding by unmeasured factors such as pretreatment functional status, other risk factors for complications or salvage surgery in those receiving primary CTRT, and patient and physician preferences. Although propensity scores may reduce selection bias, they can only control for observed characteristics. Other unmeasured factors may be unbalanced, resulting in biased estimates of the association between treatment and outcome. 47 Additionally, we may have underestimated rates of treatment complications because Medicare claims are likely to reflect the most serious diagnosis-those requiring physician evaluation, a hospital stay, or a medical procedure. 48 Finally, whereas the complications that we identified are likely associated with physical function, social function, and quality of life, we were not able to directly assess these important endpoints.
CONCLUSION
The objective of larynx-preservation therapy is to offer improved function and quality of life in patients with advanced laryngeal cancer, without compromising survival. Our analysis suggests that, although this may be the case for many patients, TL remains an important treatment option in certain older patientsparticularly patients with extensive disease. Treatment selection is complex and multifactorial; however, Fig. 2 . Selected characteristics of patients in propensity score quintile 5 compared with quintiles 1-4.* *Quintile 5 represents patients with the highest predicted probability of receiving a total laryngectomy, based on age, sex, race, census tract median income, marital status, urbanrural residence, geographic region, tumor site, clinical T stage, lymph node involvement, comorbidity score and year of diagnosis. Income quartile 1 is lowest quartile of median income in census tract of residence.
and individual patient factors such as functional status and personal preference-in addition to institutional factors including support services and surgical expertise-should play a fundamental role in treatment decisions.
